Member of the Association of American Physicians
Daniel R. Kuritzkes spends much of his time researching Immunology, Virology, Drug resistance, Acquired immunodeficiency syndrome and Internal medicine. Specifically, his work in Virology is concerned with the study of Zidovudine. His Drug resistance study combines topics in areas such as Reverse transcriptase, Bioinformatics, Regimen, Genotype and Drug.
His work in Acquired immunodeficiency syndrome addresses subjects such as Intensive care medicine, which are connected to disciplines such as Clinical research. Daniel R. Kuritzkes has researched Internal medicine in several fields, including Efavirenz, Oncology and Reverse-transcriptase inhibitor. His Viral load research is multidisciplinary, relying on both Viremia and Antibody.
His primary scientific interests are in Virology, Immunology, Viral load, Virus and Internal medicine. The Virology study combines topics in areas such as Mutation, Reverse transcriptase and Drug resistance. In his research on the topic of Immunology, Clinical trial and Intensive care medicine is strongly related with Acquired immunodeficiency syndrome.
His study focuses on the intersection of Viral load and fields such as Ritonavir with connections in the field of Lopinavir. His Virus research incorporates themes from RNA and CCR5 receptor antagonist. The various areas that Daniel R. Kuritzkes examines in his Internal medicine study include Gastroenterology, Efavirenz, Oncology and Reverse-transcriptase inhibitor.
His main research concerns Immunology, Viral load, Virology, Antiretroviral therapy and Immune system. His Immunology research is multidisciplinary, incorporating elements of Hematopoietic stem cell transplantation, Clinical trial, Acquired immunodeficiency syndrome and Cohort. The concepts of his Viral load study are interwoven with issues in Viremia, Internal medicine, Lymphocyte, Viral rebound and Viral replication.
Particularly relevant to Lentivirus is his body of work in Virology. His studies in Antiretroviral therapy integrate themes in fields like MEDLINE and Intensive care medicine. His Immune system study incorporates themes from Virus, Lymphatic system and Antibody.
Daniel R. Kuritzkes mostly deals with Viral load, Immunology, Virology, RNA and Antiretroviral therapy. His work deals with themes such as Preventive healthcare, Viremia, Integrase inhibitor, Internal medicine and Viral replication, which intersect with Viral load. His study in Immune system and Virus falls within the category of Immunology.
His Virology research integrates issues from Cell and Motion sensing. Daniel R. Kuritzkes combines subjects such as Autologous transplantation, Stem cell and Intensive care medicine with his study of Antiretroviral therapy. His Lamivudine study combines topics from a wide range of disciplines, such as Reverse transcriptase, Drug development and Zidovudine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Update of the Drug Resistance Mutations in HIV-1.
Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Huldrych F Gunthard.
Topics in HIV medicine : a publication of the International AIDS Society, USA (2008)
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
Pereyra F;Jia X;McLaren Pj.
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Jacob P. Lalezari;Keith Henry;Mary O'Hearn;Julio S.G. Montaner.
The New England Journal of Medicine (2003)
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
Diane E. Bennett;Ricardo J. Camacho;Dan Otelea;Daniel R. Kuritzkes.
PLOS ONE (2009)
Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
Martin S. Hirsch;Françoise Brun-Vézinet;Richard T. D'Aquila;Scott M. Hammer.
HIV viral load markers in clinical practice
M S Saag;M Holodniy;D R Kuritzkes;W A O'Brien.
Nature Medicine (1996)
Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
M S Hirsch;B Conway;R T D'Aquila;V A Johnson.
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
Roy M. Gulick;Roy M. Gulick;Heather J. Ribaudo;Cecilia M. Shikuma;Stephanie Lustgarten.
The New England Journal of Medicine (2004)
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Martin S. Hirsch;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway.
Clinical Infectious Diseases (2003)
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
Joseph J. Eron;Sharon L. Benoit;Joseph Jemsek;Rodger David MacArthur.
The New England Journal of Medicine (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: